StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
BSL.SI$0.95-1.55%
Fair $0.95+0.0%

BSL.SI

Raffles Medical Group Ltd

Healthcare / Medical Care FacilitiesSES

$0.95

-0.01 (-1.55%)

Fairly Valued+0.0%Fair Value $0.95Fund rank 37/100 · Data gapFallback financials|
SA 42/C
F-Score: 7/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 24% · confianza 25%

FCF escenarios

weak_data · normalized FCF $91.3M · quality 77.3/100

Data gap 37/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 74/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

42/100

C

Piotroski

7/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · BSL.SILocal privado en este navegador · Raffles Medical Group Ltd
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$1.7B

P/E

23.8x

↑

EV/EBITDA

10.7x

↓

ROE

6.7%

↑

Gross Margin

65.0%

↑

Debt/Equity

0.08

↓
52-Week Range$1
$1$1

TradingView lightweight chart

BSL.SI price, volumen y niveles de valoración

Último $0.950Periodo +260.8%
Fair value: $0.950

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

-2.4%

FCF CAGR

-18.9%

FCF margin

11.9%

FCF / Net income

1.29x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $765.3M · net income $70.6M · FCF $91.3M

2022-FY → 2025-FY

Gross margin

65.0%-11.2% pts

Operating margin

11.7%-14.3% pts

Net margin

9.2%-8.2% pts

FCF margin

11.9%-8.8% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$765.3M$765.3M$751.6M$706.9M$822.9M
Net Income$70.6M$70.6M$62.2M$90.2M$143.2M
EBITDA$142.2M$142.2M$135.8M$163.8M$238.4M
EPS——0.030.050.08
Gross Margin65.0%65.0%64.7%67.8%76.2%
Operating Margin11.7%11.7%11.5%16.4%26.0%
Net Margin9.2%9.2%8.3%12.8%17.4%
Balance Sheet
Debt/Equity0.080.080.080.110.09
Current Ratio1.311.31———
Cash Flow
Free Cash Flow$91.3M$91.3M$65.3M$167.4M$170.9M
Returns
ROE6.7%6.7%5.9%8.8%14.1%
Valuation
P/E23.7523.7524.8521.9918.51
EV/EBITDA10.7210.729.4910.6610.46
P/B1.651.651.471.932.62
Growth & Yield
Revenue Growth1.8%1.8%6.3%-14.1%—
EPS Growth——-30.7%-37.2%—
Dividend Yield3.1%3.1%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +0.0%

Total return

+0.0%

Start / end P/E

n/dx → n/dx

EPS bridge

0.03 → n/d

Residual

-3.1%

EPS growthn/d
Multiple reratingn/d
Dividend+3.1%
Residual / FX / buybacks / cross-term-3.1%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.